SCHEMBL2647700

SCHEMBL2647700

CCCCc1c(C(C)C)cc(C(C)C)c(CO)c1-c1ccc(F)cc1O

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 18/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648117 0.96 GCGR (0.73) GCGR
SCHEMBL2648260 0.95 GCGR (0.71) GCGR
SCHEMBL2648294 0.92 GCGR (0.60) GCGR
SCHEMBL2647674 0.87 GCGR (0.56) GCGR
SCHEMBL2650211 0.86 GCGR (0.69) GCGR
SCHEMBL2648415 0.84 GCGR (0.64) GCGR
SCHEMBL2649074 0.84 GCGR (0.93) GCGR
SCHEMBL2648734 0.83 GCGR (0.69) GCGR
SCHEMBL2649026 0.83 GCGR (0.68) GCGR
SCHEMBL2650641 0.82 GCGR (0.68) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US claimed
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed
EP-0934274-A1 SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS Bayer Corporation (US) 1999-08-11 EP disclosed
WO-1998004528-A2 SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS BAYER CORPORATION (US) 1998-02-05 WO disclosed